Register for our free email digests:
Vifor Pharma Group
http://www.viforpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vifor Pharma Group
Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.
Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma